AAEAAQAAAAAAAARqAAAAJGRiYjY0ZGVjLWMxYTgtNDg3Ny05NmE3LTYzYjdjOWU3ZDkxMw.png

New Data and Award-Winning Research presented on OMNIBotics™ Robotic-Assisted Total Knee Replacement Technology at Two Prestigious Conferences

Posted On October 18, 2016 By OrthoSpineNews In Robotics /

RAYNHAM, Mass., Oct. 18, 2016 /PRNewswire/ — OMNIlife science™, Inc. (“OMNI™”), an established medical technology company targeting the $15 billion global hip and knee replacement device market, announced that several presentations about their OMNIBotics technology were featured early this month at both the International Congress for Joint Reconstruction (ICJR) Transatlantic Orthopaedic Conference in New York City and at the International Society for Technology in Arthroplasty (ISTA) Annual World Congress in Boston. The selection of these papers confirms OMNI’s leadership position in robotic-assisted total knee replacement technology, with more than 10,000 OMNIBotics procedures performed worldwide.

The ICJR focuses on providing a comprehensive orthopaedic learning experience for their members, delivering timely and relevant education. Attendees learned about OMNIBotics technology in an oral poster presentation and three video poster presentations. The oral poster presentation “Surgical Efficiency and Early Patient Satisfaction In Imageless Robotic-Assisted Total Knee Arthroplasty” by John Keggi, M.D., Connecticut Joint Replacement Institute, Hartford, CT was honored with the 2016 Transatlantic Orthopaedic Congress Award of Excellence for an Oral Scientific Poster: Knee, for the exceptional quality of the research presented.

The ISTA Annual World Meeting, with 600 attendees, provides a forum for emerging technologies in orthopaedics to be discussed between surgeons, engineers, and industry with a goal of developing and implementing optimal technologies for patients in a collaborative manner. OMNIBotics was highlighted in three podium presentations and one e-poster combined with a short talk.

Featuring the research of orthopaedic surgeons Leonid Dabuzhsky, M.D. (Melrose-Wakefield Hospital, Boston, MA) and John Keggi, M.D. (Connecticut Joint Replacement Institute, Hartford, CT), presentation topics ranged from studies about the learning curve, surgical efficiency, and patient satisfaction with OMNIBotics robotic-assisted total knee replacement, to their experience with innovative emerging OMNI technologies in ligament tensioning and gap balancing. One study conducted and presented by Dr. Dabuzhsky demonstrated a significant reduction in post-operative manipulation rates when using the OMNIBotics system with ligament balancing versus another competitive technology.

These topics illustrate the interrelationship between technology, clinical efficacy, and value that OMNI believes is vital in the new fiscal paradigm in orthopaedics, the Comprehensive Care for Joint Replacement (CJR) bundled payment model, introduced by the Centers for Medicare and Medicaid Services (CMS) in 2015. OMNI, in conjunction with their consulting surgeon teams, is on the leading edge of developing and using robotic technology to reduce overall cost of joint replacement by improving outcomes without the hospital assuming the burden of a significant capital investment.

“Relevant clinical data was presented at the ISTA and ICJR Meetings, further supporting the OMNIBotics Robotic Assisted Total Knee Replacement procedure as a cost-effective surgical option suited to the value-based hospital reimbursement environment we now serve” commented Rick Randall, OMNI CEO. “Improved OMNIBotics outcomes metrics such as surgical efficiency, post-operative patient satisfaction and reduction in hospital readmissions for costly manipulations under anesthesia were reported from the podium. In addition, promising cadaveric test results using the company’s next generation robotic knee replacement technology for advanced soft tissue balancing were also presented at both meetings”.

About OMNI

OMNI is a privately held company with a proprietary robotic platform, OMNIBotics™, which allows surgeons to conduct patient-specific total knee surgery designed to enhance patient satisfaction and reduce hospital costs. In addition, OMNI designs, engineers, manufactures and distributes a wide range of proprietary hip and knee implants and is focused on providing cutting edge technologies to transform outcomes in joint replacement surgery and improve patient care. For more information about OMNI, please visit www.omnils.com.

Forward-Looking Statements

Statements in this press release concerning the future business, operations and prospects of OMNIlife science, Inc., including its plans specific to OMNIBotics systems, as well as statements using the terms “plans,” “believes” or similar expressions are “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management’s current expectations and are subject to a number of factors and uncertainties. Information contained in these forward-looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors include, among others, changes in competitive conditions and pricing in OMNI’s markets, decrease in the demand for OMNI’s products, delays in OMNI’s product research and development cycles, decreases in the use of OMNI’s principal product lines or in procedure volume, unanticipated issues in complying with domestic or foreign regulatory requirements related to OMNI’s current products or securing regulatory clearance or approvals for new products or upgrades or changes to OMNI’s current products, the impact of the United States healthcare reform legislation on hospital spending and reimbursement, any unanticipated impact arising out of the securities class action or any other litigation, inquiry, or investigation brought against OMNI, increases in costs of OMNI’s sales force and distributors, and unanticipated intellectual property expenditures required to develop, market, and defend OMNI’s products. OMNI cannot guarantee any future results, levels of activity, performance or achievement. OMNI undertakes no obligation to update any of its forward-looking statements after the date of this press release

Contact

Cindy Holloway, Director of Marketing Communications

Phone: (508) 824-2444

cholloway@omnils.com

Logo – http://photos.prnewswire.com/prnh/20161018/429923LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-data-and-award-winning-research-presented-on-omnibotics-robotic-assisted-total-knee-replacement-technology-at-two-prestigious-conferences-300346916.html

Titan Medical and Ximedica Resume Development of the Sport Surgical System

Posted On October 14, 2016 By OrthoSpineNews In Robotics /

TORONTO, ON–(Marketwired – October 13, 2016) – Titan Medical Inc. (TMD.TO) (TITXF) today reported that the Company and its principal development partner, Ximedica LLC have reached agreement on the initiation of an acceptable development plan for the SPORT™ Surgical System. The agreement is effective immediately and is focused on Titan’s previously announced Human Factors and Usability Trials milestones for the SPORT system.

“Ximedica is a valued partner and this agreement enables us to resume the development of the SPORT Surgical System,” commented John Barker, Interim CEO of Titan Medical Inc. “This agreement and the decisions by the Board of Directors earlier this week demonstrate the committed effort of our company to advance the SPORT Surgical System.”

“We believe the SPORT Surgical System represents a significant technology and everyone at Ximedica is proud to be associated with its continued development,” commented Randall Barko, President and CEO of Ximedica. “Our development team is re-engaging and our objective is to deliver on Titan’s milestones.”

As the new development plan proceeds the Company will report on its progress.

About Titan Medical Inc.

Titan Medical Inc. is a Canadian public company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”). The Company’s SPORT™ Surgical System, currently under development, includes a surgeon-controlled robotic platform that incorporates a 3D high-definition vision system and multi-articulating instruments for performing MIS procedures through a single incision. The surgical system also includes a surgeon workstation that provides a surgeon with an advanced ergonomic interface to the robotic platform for controlling the instruments and provides a 3D high-definition endoscopic view of inside a patient’s body. The SPORT Surgical System is designed to enable surgeons to perform a broad set of surgical procedures for general abdominal, gynecologic, and urologic indications. For more information, visit the Company’s website at www.titanmedicalinc.com.

Forward-Looking Statements

This news release contains “forward-looking statements” which reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the Company’s Annual Information Form dated March 30, 2016 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.

Mazor Robotics Receives First Pre-Launch Orders for Mazor X System; Reports Record System Purchase Orders During Third Quarter

Posted On October 10, 2016 By OrthoSpineNews In Robotics /

October 10, 2016

CAESAREA, Israel–(BUSINESS WIRE)–Mazor Robotics Ltd. (TASE:MZOR; NASDAQGM:MZOR), a pioneer and a leader in the field of surgical guidance systems, today announced that it received purchase orders for 25 systems during the third quarter ended September 30, 2016 including pre-launch orders for the recently unveiled Mazor X, a transformative guidance platform for spine surgeries. The Mazor X will be commercially launched at the North American Spine Society (NASS) annual meeting in Boston, MA October 26-29.

“The market’s response to the Mazor X is exceptional, exceeding our early expectations,” commented Ori Hadomi, Chief Executive Officer. “Customers who first experience the Mazor X at our training centers are quickly realizing the increased benefits of the system and they have already placed pre-launch orders. Mazor’s expanded portfolio of products, which now includes both the Mazor X and Renaissance systems, is responsible for the record number of purchase orders we received in the third quarter. As we move into the fourth quarter, we expect to build our momentum in the market as the Mazor X is launched, maximize our presence at NASS and our strategic partnership with Medtronic continues to be implemented.”

The 25 system purchase orders during the quarter included:

Three Mazor X pre-orders that the Company expects to deliver to U.S. customers by the end of the 2017 first quarter.
Four Renaissance systems ordered by U.S. customers were delivered during Q3 2016.
Three Renaissance systems ordered by distribution partners in the International Market.
15 Mazor X systems ordered by strategic partner Medtronic, four of which were delivered in the 2016 third quarter.

During the third quarter, Mazor delivered a previously ordered Renaissance system to a distribution partner in the international market.

As previously reported, the Company recently implemented a policy enabling new Renaissance system customers to exchange to the Mazor X following the launch. Therefore, revenue from system sales with exchange option will be deferred until the Mazor X orders are supplied or the exchange option expires. The Company expects total third quarter revenue, including system sales and recurring revenues, to be approximately $7.5 million.

Mazor Robotics ended the third quarter with an installed base of 131 Renaissance systems globally, including 79 in the U.S., the Company’s primary growth market. The Company currently intends to report its complete financial results for the third quarter ended September 30, 2016 in November and will issue a press release with the date, time and dial in and webcast details.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the market’s response to Mazor X, the benefits of Mazor X, Mazor’s expectations about market momentum, the expected delivery of Mazor’s systems, expected revenue for the third quarter and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC) including those discussed under the heading “Risk Factors” in Mazor’s annual report on Form 20-F filed with the SEC on May 2, 2016 and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.

About Mazor

Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary technologies and products aimed at redefining the gold standard of quality care. Mazor Robotics Guidance Systems enable surgeons to conduct spine and brain procedures in a more accurate and secure manner. For more information, please visit www.MazorRobotics.com.

Contacts

Investors
Michael Polyviou, 212-850-6020
mpolyviou@evcgroup.com
or
Doug Sherk, 415-652-9100
dsherk@evcgroup.com

US $5 million granted to spinal cord injury robotics research project

Posted On October 5, 2016 By OrthoSpineNews In Financial, Robotics /

5th October 2016

Studies have shown that activity-based interventions can offer a promising approach to the improvement of motor function following spinal cord injury. Sunil Agrawal, professor of mechanical engineering and of rehabilitation and regenerative medicine at Columbia Engineering (New York City, USA) is at the forefront of research efforts to improve recovery through the development of novel robotic devices and interfaces that help patients retrain their movements.

One of Agrawal’s current projects, “Tethered pelvic assist device (TPAD) and epidural stimulation for recovery of standing in spinal cord injured patients,” has recently won a five-year US$5 million grant from the New York State Spinal Cord Injury Board. The project is a collaboration with co-principal investigator, Susan Harkema, and Claudia Angeli in the Department of Neurological Surgery at the University of Louisville, USA, and Joel Stein, chair of the Department of Rehabilitation and Regenerative Medicine, and Ferne Pomerantz , assistant professor of rehabilitation and regenerative medicine in the Department of Rehabilitation and Regenerative Medicine, both at Columbia University Medical Center (New York City, USA). Agrawal’s focus is on improving the effectiveness of stand/balance training during spinal cord injury rehabilitation by using a unique robotic system—Tethered Pelvic Assist Device (TPAD)—invented in his Robotics and Rehabilitation (ROAR) Laboratory at Columbia Engineering.

Agrawal’s TPAD is a wearable, light-weight cable-driven robot that can be programmed to provide both motion perturbations to the pelvis as well as corrective forces to stabilise it. The Agrawal and Harkema groups will combine their expertise and technologies for balance training of SCI patients during standing.

Harkema’s group at the University of Louisville has pioneered the use of activity-based rehabilitation for spinal cord injury patients and, more recently, the use of epidural stimulation of the lumbosacral spinal cord during stand training of spinal cord injury subjects. Their results show the effectiveness of stand training of spinal cord injury patients by combining epidural stimulation and principles of motor learning. The group has successfully shown this strategy to work with the most severely injured individuals.

Even though these patients are able to stand, they are unable to maintain balance. As a result, they have difficulty in transferring this skill to the activities of daily life.

“We are using this technology for the first time to enhance the effectiveness of balance recovery during stand training of spinal cord injury survivors,” says Agrawal, who has, in the past, received funding from the US National Institutes of Health to work extensively on gait training of stroke survivors by designing robotic exoskeletons that can be worn by patients during training in the rehab clinics. “Robotic exoskeletons are typically designed to assist in training of human movements during the swing phase of the gait, but there are currently no robotic devices that can effectively be used for posture and balance training during standing.”

Agrawal’s TPAD consists of a pelvic belt with multiple cables connected to motors, a real-time motion capture system, and a real-time controller to regulate the tensions in the cables. The device is programmed to provide pelvic forces in any direction and respond to motions of the human body. Its tethers can also be configured to apply symmetric or asymmetric forces on the pelvis, as needed by an intervention. The system design allows placement of motors and pulleys on a frame to achieve cable configurations to be able to apply corrective or perturbative forces on the pelvis in any direction, whether these be up, down, or sideways.

“Our TPAD, along with its extensions, can be used in a variety of interventions during walking or standing,” adds Agrawal, who is also a member of Columbia’s Data Science Institute. “So sensory input, repetition, and challenged behaviour can drive the spinal networks to adapt appropriately and generate functional activation across the level of injury. This functional load bearing and acquisition of balance can have a tremendous impact on the continued health and quality of life of individuals with spinal cord injury.”

In addition to the TPAD grant, Agrawal was honored recently by the American Society of Mechanical Engineering with its Machine Design Award for his “seminal contributions to the design of robotic exoskeletons for gait retraining of stroke patients.”

Ekso Bionics® Launches Ekso GT with Smart Assist

Posted On October 5, 2016 By OrthoSpineNews In Robotics /

RICHMOND, Calif., Oct. 04, 2016 (GLOBE NEWSWIRE) — Ekso Bionics Holdings, Inc. (EKSO), a robotic exoskeleton company, today announced it recently has shipped the first device incorporating SmartAssist, its next generation gait therapy software, allowing the company to expand the range of patients who can participate in robotic therapy.

The SmartAssist technology, which is currently available for Ekso GT devices in Europe, offers new options to therapists for customizing training in gait and balance. The SmartAssist software allows physical therapists to vary the support of the device for each leg independently – from full power to free walking – and thereby meet the specific needs of patients. This capability enables the Ekso GT to rehabilitate a larger range of patients, from those too weak to walk to those who are nearly independent.

“SmartAssist has definitely made a change to how we use the exoskeleton and broadened the spectrum of conditions we can use it for,” commented Louis Martinelli, Neurological Physiotherapist at Hobbs Rehabilitation in Winchester, England. “The therapists can now adjust the settings to vary the support we give, not only to the swing phase but the stance phase of gait, giving the participant access to an optimal walking pattern.”

The Ekso GT with SmartAssist is a comprehensive gait therapy tool that can support a broad spectrum of patients. The technology allows patients to be more actively engaged in their rehabilitation than ever before, enabling more activity with higher intensity than previously possible.

“Ekso GT with SmartAssist software was developed to expand the applications for use within clinics. The addition of pre-gait exercises have facilitated earlier mobility for some patients who could not have otherwise been mobile and our new FreeGait advanced mode can help patients progress to community ambulation,” commented Thomas Looby, chief executive officer of Ekso Bionics. “We are excited to offer this as another life changing solution for patients who use our exoskeletons for rehabilitation.”

The SmartAssist software is not yet available in the United States.

About Ekso Bionics^®
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.

About Ekso™ GT
Ekso™ GT is the first FDA cleared exoskeleton cleared for use with stroke and spinal cord injuries from L5 to C7. The Ekso GT with smart Variable Assist™ (marketed as SmartAssist outside the U.S.) software is the only exoskeleton available for rehabilitation institutions that can provide adaptive amounts of power to either side of the patient’s body, challenging the patient as they progress through their continuum of care. The suit’s patented technology provides the ability to mobilize patients earlier, more frequently and with a greater number of high intensity steps. To date, this device has helped patients take more than 55 million steps in over 120 rehabilitation institutions around the world.

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company’s future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain adequate financing to fund the Company’s operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company’s products, the Company’s failure to achieve broad market acceptance of the Company’s products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company’s medical device products, the failure to obtain or maintain patent protection for the Company’s technology, failure to obtain or maintain regulatory approval to market the Company’s medical devices, lack of product diversification, existing or increased competition, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.

The Center for Musculoskeletal Disorders in Englewood, NJ and Mazor Robotics Announce the First Installation of the Renaissance(R) System in an Ambulatory Outpatient Setting in the Northeast

Posted On September 29, 2016 By OrthoSpineNews In Robotics /

ORLANDO, Fla., Sept. 29, 2016 (GLOBE NEWSWIRE) — Mazor Robotics Inc., a developer of innovative guidance systems and complementary products, and The Center for Musculoskeletal Disorders (CMD), today announced the first installation of the Renaissance system in an ambulatory outpatient setting in the Northeast.

CMD, located in Englewood, NJ, is a joint private practice including The Center for Spinal Disorders, The Center for Hand Disorders and The Center for Pain Management. CMD’s spine surgeons, Drs. Jonathan Lewin, Seth Grossman and Vagmin Vora, assisted by Isaac Abramchayev, PA, will be using Renaissance. Drs. Steven Horowitz and Jonathan Simhaee, who head the pain management division, also support the new technology, along with the orthopedic head of the practice, Dr. Raz Winiarsky.

“With Mazor’s Renaissance system, we now have a unique opportunity to provide spine surgery patients access to the latest technology in an outpatient setting,” said Spine Surgeon Dr. Jonathan Lewin. “The system is a great addition to our comprehensive care practice.”

“The technology is innovative and forward thinking. The pre-operative platform helps put the surgeon at ease about placement of metal hardware around very vital structures,” said the practice’s PA, Isaac Abramchayev. “The intra-operative hardware is precise and easy to apply into the normal routine. For too long, spinal surgery has relied on estimation and guessing. This technology is set to theoretically and practically change the way spinal surgery is approached from a surgical and perioperative team standpoint.”

The Renaissance system uses advanced 3D planning and mechanical guidance with 1.5mm accuracy to provide surgeons with a powerful solution for minimally invasive and percutaneous fusions, complex spinal deformity and trauma cases. Access Mazor Robotics series of ‘How Renaissance Works’ videos here.

About Mazor

Mazor Robotics believes in healing through innovation by developing and introducing revolutionary technologies and products aimed at redefining the gold standard of quality care. Mazor Robotics Guidance Systems enable surgeons to conduct spine and brain procedures in a precise manner. For more information, please visithttp://www.MazorRobotics.com .

About The Center for Musculoskeletal Disorders (CMD)

The Center for Musculoskeletal Disorders (CMD) is a formalized joint practice including The Center for Spinal Disorders, The Center for Hand Disorders and The Center for Pain Management. Since the three centers have long worked together to provide cohesive care to the community, our newly integrated practice will continue our steadfast servitude to our patients. Our specialty-trained physicians and staff share the common philosophy of highly personalized care. We stress non-surgical solutions whenever possible and use cutting-edge medical and surgical techniques to customize advanced treatments for our patients’ needs.

AAEAAQAAAAAAAAjkAAAAJGFjMWZiMzRjLTVlYWEtNDU2Mi04Mzk3LWNhNDIwMzkzZGM4NQ.jpg

Verb’s Huennekens unveils vision of next-gen robotic surgery

Posted On September 29, 2016 By OrthoSpineNews In Robotics /

by Stacy Lawrence | Sep 28, 2016

Verb Surgical is working on what it sees as “Surgery 4.0”: the next iteration of surgery that incorporates robotics, advanced visualization, machine learning, data analytics and connectivity. It expects that its technology could translate into real access for billions globally who currently don’t have access to surgery by lowering costs and reducing the training threshold.

Along with Johnson & Johnson’s ($JNJ) Ethicon and Alphabet’s ($GOOG) Verily, Verb expects to have a fully working prototype surgical system by year end. Ethicon already divulged earlier this year that there was a prototype of the robotic system. A surgical system isn’t expected to be on the market, though, until 2020.

“We envision a future in surgery where we move from having a mainframe computer to a PC on every desk to a cell phone in every pocket,” Verb President and CEO Scott Huennekens toldFierceMedicalDevices. “Everybody has access at a much lower cost with a much lower threshold for training.”

He said that Ethicon is specifically contributing its surgical instrumentation, while Verily and Google are bringing to the table data analytics and machine learning tech. The expectation is that these surgical systems will talk to each other–and learn systematically.

READ THE REST HERE

Mazor Robotics to Present at the Ladenburg Thalmann Annual Healthcare Conference

Posted On September 26, 2016 By OrthoSpineNews In Robotics /

CAESAREA, Israel–(BUSINESS WIRE)– Mazor Robotics Ltd. (TASE: MZOR; NASDAQGM: MZOR), a leading developer of innovative bone mounted surgical guidance systems, announced today that Sharon Levita, Chief Financial Officer, is scheduled to present an overview of the Company at the Ladenburg Thalmann Annual Healthcare Conference on Tuesday, September 27, 2016 at 11:30 a.m. ET (6:30 p.m. IST). The conference will be held at the Sofitel Hotel in New York City.

A live webcast and subsequent archived replay of the Company’s presentation may be accessed via the investor relations section of the Company’s website. To access the webcast, please use the following address http://wsw.com/webcast/ladenburg2/mzor or visit www.mazorrobotics.com and select Investor Relations.

In addition the Company announced that it will report third quarter system orders on Monday, October 10^th.

About Mazor

Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary robotic-based technology and products aimed at redefining the gold standard of quality care. Mazor Robotics Renaissance® Guidance System enables surgeons to conduct spine and brain procedures in a more accurate and secure manner. For more information, please visit www.MazorRobotics.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160926005911/en/

Contacts

U.S. Contacts: EVC Group
Investors
Michael Polyviou, 212-850-6020
mpolyviou@evcgroup.com
Doug Sherk, 415-652-9100
dsherk@evcgroup.com
or
Media
David Schemelia, 646-201-5431
dave@evcgroup.com

Source: Mazor Robotics Ltd.

Phoenix VA Health Care System Deploys Germ-Zapping Robots to Enhance Veteran Safety; Xenex Robots Destroy Pathogens that Pose a Risk to Patients, Staff & Family Members

Posted On September 15, 2016 By OrthoSpineNews In Robotics /

September 15, 2016 11:44 AM Eastern Daylight Time

PHOENIX–(BUSINESS WIRE)–The Phoenix Veterans Affairs (VA) Health Care System is the first hospital in Arizona to deploy Xenex LightStrike™ Germ-Zapping Robots™ to destroy deadly germs and bacteria lurking on hospital surfaces that can cause hospital acquired infections (HAI). The portable room disinfection system utilizes pulsed xenon ultraviolet (UV) light and is effective against even the most dangerous superbugs and multi-drug resistant organisms (MDRO), including methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile (C.diff), VRE, norovirus and influenza. Additionally, the Xenex Germ-Zapping Robot has been proven effective against both the Ebola virus and Anthrax, and can easily be incorporated into a facility’s disease containment and biodefense strategy.

Pulsed xenon UV disinfection is an environmentally-friendly technology and exceeds both Presidential Executive Orders and VA Directives regarding sustainability and green procurement. Prior to implementing Xenex, the Phoenix VA used a mercury UV disinfection system (mercury is toxic) and as a result, the facility’s OR experienced a degradation of materials including the cracking and yellowing of plastics. The materials damage associated with continuous mercury UV is a newly identified problem associated with mercury UV technology and the Phoenix VA was among the first in the nation to identify this issue.

To date, 20 peer-reviewed studies showing the effectiveness of pulsed xenon UV in reducing pathogens from the environment have been published, including eight studies that reported a decrease in patient infection rates when the pulsed xenon UV technology was used. Five of the environmental studies were accomplished by VA researchers including Dr. Chetan Jinadatha, Chief of Infectious Disease, Central Texas Veterans Health Care System, who found manual cleaning plus pulsed xenon UV light disinfection was far more effective than traditional cleaning methods at eliminating MRSA bacteria and was 23 percent faster when integrated into the room cleaning process. More importantly, numerous healthcare organizations using Xenex LightStrike robots have reported significant reductions in C.diff, MRSA, VRE and Surgical Site Infection (SSI) rates. This is evidenced in multiple published peer-reviewed outcome studies showing 50-100 percent reductions in HAI rates.

In addition to being the first hospital in Arizona, the Phoenix VA is the first VA facility in the Southwest Health Care Network (VISN 18) to deploy this innovative, leading-edge patient safety technology. The Phoenix VA joins 40 VA facilities and over 350 hospitals across the nation who have added the Xenex LightStrike robot to their disinfection arsenals. During the implementation, as a tribute to the military, the Phoenix VA named its six LightStrike robots after the Commander-in-Chief and five sister services: Chief, Army, Navy, Air Force, Marines, and Coast Guard.

“We want to do everything possible to provide a clean environment and enhance patient safety at our facility to reduce the risk of hospital acquired infections,” said Kenneth Carter, Chief of Environmental Management Services, Phoenix VA. “One infection is one too many, so enlisting the help of the Xenex robots will help us achieve our goal of zero infections. This investment in a proven technology is important and underscores our commitment to patient care and the veterans we serve.”

The Xenex Germ-Zapping Robots are an adjunctive step in the hospital’s cleaning process. Operated by the hospital’s EVS team, they are brought into a room after traditional cleaning has taken place to destroy microscopic germs and bacteria that may be lurking on high touch surfaces, such as bed rails, tray tables, door knobs and remote controls. The portable Xenex system can disinfect a typical patient or procedure room in four or five minute cycles (depending on robot model) without warm-up or cool-down times. It can be used in any department and in any unit within a healthcare facility, including isolation rooms, operating rooms, general patient care rooms, contact precaution areas, emergency rooms, bathrooms and public spaces.

Xenex Disinfection Services

Xenex’s patented Full Spectrum^TM pulsed xenon UV room disinfection system is used for the advanced disinfection of healthcare facilities. Due to its speed and ease of use, the Xenex system has proven to integrate smoothly into hospital cleaning operations. Xenex’s mission is to save lives and reduce suffering by eliminating the deadly microorganisms that cause hospital acquired infections (HAIs). The company is backed by well-known investors that include Malin Corporation, Battery Ventures, Targeted Technology Fund II and RK Ventures. For more information, visit Xenex.com.

Contacts

Phoenix VA Health Care System
Paul Coupaud, 602-200-6036
Paul.coupaud@va.gov
or
Xenex
Melinda Hart, 210-240-4669
melinda.hart@xenex.com

TransEnterix, Inc. Unveils New Brand Identity for Robotic Surgical System

Posted On September 7, 2016 By OrthoSpineNews In Robotics /

September 07, 2016

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced the launch of a new brand identity for the ALF-X Robotic Surgical System, which henceforth will be known as The Senhance™ Surgical Robotic System (“Senhance”).

“We are pleased to announce the new brand identity for our multiport surgical robotic system,” said Todd M. Pope, President and CEO of TransEnterix. “This is a pivotal point in our growth strategy and we believe Senhance speaks directly to the benefits experienced with our system.”

Mr. Pope continued: “Our goal is to advance minimally invasive surgery and the tools surgeons have at their disposal to provide patients with the best possible care while also providing a more attractive value proposition to the hospital. Senhance is designed to enhance laparoscopic surgery and specifically empowers the senses of the surgeon in ways that were never previously possible. The security of haptics and the convenience of eye sensing camera control are meaningful ways that technology can provide a further extension of the surgeon’s skill.”

The new logo, evocative of a thumb-print combined with circuitry, is a representation of the strong connection that Senhance provides between the surgeon and technology.

Senhance carries the CE Mark for use in general surgery, gynecology, urology and thoracic surgery. TransEnterix is actively preparing a submission for U.S. FDA Clearance for Senhance.

About TransEnterix

TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the commercialization of the Senhance Surgical Robotic System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control. The company is also developing the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform. The Senhance Surgical Robotic System has been granted a CE Mark but is not currently available for sale in the United States. For more information, visit the TransEnterix website at www.transenterix.com.

Forward Looking Statements

This press release includes statements relating to The Senhance™ Surgical Robotic System and the SurgiBot™ System and our current regulatory and commercialization plans for these products. These statements and other statements regarding our future plans and goals constitute “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations, including whether Senhance speaks directly to the benefits both surgeons and patients experience with our Senhance system; whether Senhance is designed to enhance laparoscopic surgery and specifically empower the senses of the surgeon in ways never before provided. For a discussion of the risks and uncertainties associated with TransEnterix’s business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K filed on March 3, 2016 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts

For TransEnterix, Inc.
Investor Contact:
Mark Klausner, +1 443-213-0501
invest@transenterix.com
or
Media Contact:
(For EU) Conrad Harrington, +44 (0)20 3178 8914
(For US) Hannah Dunning, +1 415-618-8750
TransEnterix-SVC@sardverb.com